114 related articles for article (PubMed ID: 38541124)
21. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Nakaigawa N; Tomita Y; Tamada S; Tatsugami K; Osawa T; Oya M; Kanayama H; Miura Y; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Kimura A
Int J Clin Oncol; 2023 Mar; 28(3):416-426. PubMed ID: 36595123
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K; Tomioka-Inagawa R; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551927
[TBL] [Abstract][Full Text] [Related]
23. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G; Claps M; Pircher C; Porcu L; Sepe P; Guadalupi V; De Giorgi U; Bimbatti D; Nolè F; Carrozza F; Buti S; Iacovelli R; Ciccarese C; Masini C; Baldessari C; Doni L; Cusmai A; Gernone A; Scagliarini S; Pignata S; de Braud F; Verzoni E
Tumori; 2023 Feb; 109(1):129-137. PubMed ID: 36447337
[TBL] [Abstract][Full Text] [Related]
24. Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Yano Y; Ohno T; Komura K; Fukuokaya W; Uchimoto T; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Azuma H
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428750
[TBL] [Abstract][Full Text] [Related]
25. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Négrier S; Campedel L; Martini D; Borchiellini D; Chahoud J; Lodi M; Barthélémy P; Hasanov E; Hahn AW; Gil T; Viswanathan SR; Bakouny Z; Msaouel P; Asim Bilen M; Choueiri TK; Albiges L; Tannir NM; Malouf GG
Oncologist; 2022 Dec; 27(12):1041-1047. PubMed ID: 35979929
[TBL] [Abstract][Full Text] [Related]
28. Cancer incidence and mortality in Poland in 2019.
Didkowska J; Wojciechowska U; Michalek IM; Caetano Dos Santos FL
Sci Rep; 2022 Jun; 12(1):10875. PubMed ID: 35760845
[TBL] [Abstract][Full Text] [Related]
29. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study).
Procopio G; Sepe P; Claps M; Buti S; Colecchia M; Giannatempo P; Guadalupi V; Mariani L; Lalli L; Fucà G; de Braud F; Verzoni E
JAMA Oncol; 2022 Jun; 8(6):910-913. PubMed ID: 35420628
[TBL] [Abstract][Full Text] [Related]
31. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
32. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab.
Iinuma K; Enomoto T; Kawada K; Fujimoto S; Ishida T; Takagi K; Nagai S; Ito H; Kawase M; Nakai C; Kawase K; Kato D; Takai M; Nakane K; Kameyama K; Koie T
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830607
[TBL] [Abstract][Full Text] [Related]
33. Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
Venugopal B; Pillai M; Powles T; Savage P; Michael A; Fife K; Klair B; Perrot V; Szabados B
Clin Genitourin Cancer; 2022 Feb; 20(1):94-94.e10. PubMed ID: 34802966
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
[TBL] [Abstract][Full Text] [Related]
35. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L; Martinez Chanza N; Farah S; Xie W; Flippot R; Braun DA; Rathi N; Thouvenin J; Collier KA; Seront E; de Velasco G; Dzimitrowicz H; Beuselinck B; Xu W; Bowman IA; Lam ET; Abuqayas B; Bilen MA; Varkaris A; Zakharia Y; Harrison MR; Mortazavi A; Barthélémy P; Agarwal N; McKay RR; Brastianos PK; Krajewski KM; Albigès L; Harshman LC; Choueiri TK
JAMA Oncol; 2021 Dec; 7(12):1815-1823. PubMed ID: 34673916
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4
Jancewicz I; Szarkowska J; Konopinski R; Stachowiak M; Swiatek M; Blachnio K; Kubala S; Oksinska P; Cwiek P; Rusetska N; Tupalska A; Zeber-Lubecka N; Grabowska E; Swiderska B; Malinowska A; Mikula M; Jagielska B; Walewski J; Siedlecki JA; Sarnowski TJ; Markowicz S; Sarnowska EA
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439305
[TBL] [Abstract][Full Text] [Related]
37. Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
Santoni M; Massari F; Grande E; Procopio G; Matrana MR; Rizzo M; De Giorgi U; Basso U; Milella M; Iacovelli R; Aurilio G; Incorvaia L; Buti S; Caffo O; Fornarini G; Carrozza F; Mollica V; Rizzo A; Farag F; Molina-Cerrillo J; Battelli N
Target Oncol; 2021 Sep; 16(5):625-632. PubMed ID: 34338966
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
[TBL] [Abstract][Full Text] [Related]
39. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
